Rory Sheehan

TL;DR: The proportion of people with intellectual disability who have been treated with psychotropic drugs far exceeds the proportion with recorded mental illness, and more evidence is needed of the efficacy and safety of psychotropics in this group, particularly when they are used for challenging behaviour.

TL;DR: Validity of clinical diagnoses were explored by establishing the stability of diagnoses over time and concurrent validity and reliability of clinicians' diagnoses of dementia against ICD‐10 and DSM‐IV‐TR diagnoses were determined.

TL;DR: Evidence is provided that people with intellectual disability are more susceptible to movement side effects of antipsychotic drugs than those without and regular medication review is essential to ensure optimal prescribing in this group.

TL;DR: Down syndrome is associated with an almost universal development of Alzheimer's disease and individuals with DS are an important population for randomized controlled trials to prevent or delay cognitive decline, though it is essential to understand the time course of early cognitive changes.

TL;DR: It is found that antipsychotics can be reduced or discontinued in a substantial proportion of adults who use them for challenging behaviour, although not always without adverse effects.